Innovent Biologics, Inc. (HKG:1801)

Innovent Biologics Ratios and Metrics

Market cap in millions HKD. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 17, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	158,076	132,265	59,956	69,333	51,403	70,547
Market Cap Growth	146.47%	120.60%	-13.53%	34.88%	-27.14%	-38.71%
Enterprise Value	140,921	125,514	54,283	63,850	44,899	59,352
Last Close Price	91.10	76.25	36.60	42.75	33.50	48.25
PE Ratio	174.18	146.09	-	-	-	-
Forward PE	47.97	42.67	-	-	-	-
PS Ratio	10.89	9.11	5.98	10.14	9.98	13.46
PB Ratio	7.34	6.14	4.30	5.02	4.24	5.56
P/TBV Ratio	7.97	6.67	4.40	5.04	4.25	5.57
P/FCF Ratio	-	-	175.32	-	-	-
P/OCF Ratio	-	-	43.78	425.78	-	-
EV/Sales Ratio	9.71	8.65	5.41	9.34	8.72	11.33
EV/EBITDA Ratio	139.79	112.49	2126.28	-	-	-
EV/EBIT Ratio	209.21	160.65	-	-	-	-
EV/FCF Ratio	-	-	158.73	-	-	-
Debt / Equity Ratio	0.14	0.14	0.22	0.29	0.30	0.24
Debt / EBITDA Ratio	2.81	2.81	50.93	-	-	-
Debt / FCF Ratio	-	-	8.81	-	-	-
Net Debt / Equity Ratio	-0.80	-0.80	-0.38	-0.59	-0.55	-0.63
Net Debt / EBITDA Ratio	-15.37	-15.37	-210.62	5.70	2.06	2.57
Net Debt / FCF Ratio	-	-	-15.72	7.56	2.11	2.11
Asset Turnover	0.44	0.44	0.45	0.33	0.27	0.30
Inventory Turnover	2.90	2.90	2.69	1.51	1.00	1.19
Quick Ratio	2.38	2.38	2.08	2.68	2.78	3.27
Current Ratio	2.63	2.63	2.35	3.00	3.29	3.79
Return on Equity (ROE)	5.01%	5.01%	-0.74%	-8.84%	-20.70%	-28.56%
Return on Assets (ROA)	1.49%	1.49%	-0.82%	-5.12%	-11.54%	-12.04%
Return on Invested Capital (ROIC)	17.28%	11.34%	-4.18%	-31.37%	-72.59%	-95.23%
Return on Capital Employed (ROCE)	2.40%	2.40%	-1.60%	-9.70%	-22.20%	-20.50%
Earnings Yield	0.57%	0.68%	-0.17%	-1.63%	-4.79%	-4.75%
FCF Yield	-	-	0.57%	-1.54%	-6.19%	-5.38%
Buyback Yield / Dilution	-6.98%	-6.98%	-4.35%	-4.67%	-2.37%	-7.27%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.